Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 13NIH 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma 4Lymphoma, T-Cell 3Prostatic Neoplasms 2Neoplasm Metastasis 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

mogamulizumab 4denileukin diftitox 4Vorinostat 4Panobinostat 4zanolimumab 3cobomarsen 3Brentuximab Vedotin 3Bexarotene 3tenalisib 2selinexor 2marizomib 2hypericin 2Vitamin B 12 2Rituximab 2Folic Acid 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2tislelizumab 1tinostamustine 1sapacitabine 1romidepsin 1resminostat 1quisinostat 1ontuxizumab 1navitoclax 1forodesine 1fludarabine phosphate 1enzastaurin 1belinostat 1abexinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Cutaneous × romidepsin × Clear all
NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Celgene

Phase 2 Completed
102 enrolled 15 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡